Glaucoma is one of the leading causes of global irreversible blindness. It is characterized by a progressive loss of retinal ganglion cells with corresponding optic nerve alterations and visual field loss. The pathophysiology of glaucoma is multifactorial and there are several clinical phenotypes.
Diagnosis of glaucoma is not always straightforward. Glaucoma slowly damages the eyes causing irreversible injury before there is any vision loss, which implies that a large number of glaucoma patients remain undiagnosed, leading to blindness. Elevated intraocular pressure (IOP) is recognized as a major risk factor for the development and progression of glaucoma and lowering IOP is currently the primary strategy of treating the disease. However, new medical treatment strategies, such as neuroprotectors and para-surgical or surgical treatments, have been proposed. Numerous clinical trials evaluating either medical, surgical, or behavioral interventions are being conducted around the world to study glaucoma, with the aim of improving its diagnosis, management, and treatment.
This Research Topic focuses on the very latest discoveries in the field of glaucoma, emphasizing novel advances in pathophysiology, diagnosis, patient treatment and rehabilitation in order to gain a better understanding of the disease.
The topics welcome include but are not limited to the following:
- Novel mechanisms and their biomarkers;
- New clinical therapeutic concepts;
- Artificial intelligence in glaucoma, i.e. detection;
- Application of artificial intelligence in glaucoma diagnosis and follow-up;
- New targets for therapy;
- Advanced medical devices, pharmacological options or surgical strategies that could be used in clinical and surgical practice.
Glaucoma is one of the leading causes of global irreversible blindness. It is characterized by a progressive loss of retinal ganglion cells with corresponding optic nerve alterations and visual field loss. The pathophysiology of glaucoma is multifactorial and there are several clinical phenotypes.
Diagnosis of glaucoma is not always straightforward. Glaucoma slowly damages the eyes causing irreversible injury before there is any vision loss, which implies that a large number of glaucoma patients remain undiagnosed, leading to blindness. Elevated intraocular pressure (IOP) is recognized as a major risk factor for the development and progression of glaucoma and lowering IOP is currently the primary strategy of treating the disease. However, new medical treatment strategies, such as neuroprotectors and para-surgical or surgical treatments, have been proposed. Numerous clinical trials evaluating either medical, surgical, or behavioral interventions are being conducted around the world to study glaucoma, with the aim of improving its diagnosis, management, and treatment.
This Research Topic focuses on the very latest discoveries in the field of glaucoma, emphasizing novel advances in pathophysiology, diagnosis, patient treatment and rehabilitation in order to gain a better understanding of the disease.
The topics welcome include but are not limited to the following:
- Novel mechanisms and their biomarkers;
- New clinical therapeutic concepts;
- Artificial intelligence in glaucoma, i.e. detection;
- Application of artificial intelligence in glaucoma diagnosis and follow-up;
- New targets for therapy;
- Advanced medical devices, pharmacological options or surgical strategies that could be used in clinical and surgical practice.